News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.
LONDON–(BUSINESS WIRE)–Element Materials Technology (Element) completed its sixth life sciences-focused acquisition in 2021, with the formal completion of the acquisition of JMI Laboratories (JMI). Element has now developed its expertise and capabilities for pharmaceutical and biopharmaceutical customers, expanding to a team of over 1,000 experts in 23 facilities across North America and Europe.
This step change in Element’s pharmaceutical and medical testing capabilities is part of its broader strategic shift to grow its global presence in life sciences and connected technologies.
Jo Wetz, CEO of Element, said, “Our expansion into life sciences and connected technologies over the past two years has given us a leadership position in these strategically important end markets. As we celebrate 10 years of being a standalone Element business, we see more and more opportunities to work closely with our customers throughout their product and testing lifecycles.
Cherie Gudz, Vice President, Life Sciences Americas, said, “In a world still facing a pandemic, the life sciences industry has never been more vital. Last year’s six acquisitions alone reinforce Element’s commitment to continue building a large-scale business in this vital industry, which is now our largest global end market. We are delighted to have JMI’s team and expertise join the Element family.”
Based in North Liberty, Iowa, JMI is a market leader in antimicrobial resistance surveillance studies used for US-FDA regulatory and new drug applications through its proprietary SENTRY antimicrobial surveillance program. It offers microbiology and molecular testing services to aid in the development of new antimicrobials and support for clinical trials. The company is CLIA accredited and capable of testing under GLP conditions. The company is distinguished by its team of highly scientific and well-published industry-recognized experts in the field, including 10 MD/PhDs with in-depth knowledge of microbiology and antimicrobials, and can consult on a wide range of topics. scientists covering epidemiology, resistance mechanisms in bacterial and fungal organisms, microbiological diagnostics and susceptibility testing methods.
The acquisition of JMI follows Element’s recently announced acquisitions, which include ALG, Avomeen, Arch Sciences, Impact Analytical, Orthokinetic, Nanosyn, complementing Element’s existing expertise and expanding its client offering.
Show source version on businesswire.com: https://www.businesswire.com/news/home/20220114005219/en/
Devan LaBrash
element@pagodapr.com
+44 (0) 131 556 0770
Source: Elemental Materials Technology
